As another non-limiting example, T7 RNA polymerase variants may encode at least mutation as described in U. In one embodiment, the modified mRNA may be formulated in a lipid-polycation complex. R 12a is H, optionally substituted alkyl, optionally substituted carboxyaminoalkyl, optionally substituted aminoalkyl e. It will be appreciated by those of skill in the art that disclosed in the Tables are potential flanking regions. Such proteins may not be present, or are essentially non-functional. As a non- limiting example, if the nucleotides in the region are GGGAGA the guanine bases may be substituted by at least 1, at least 2, at least 3 or at least 4 adenine nucleotides.
|Date Added:||27 April 2007|
|File Size:||22.48 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with an organic derivatizing agent that is capable of reacting with selected side-chains or terminal residues, or by harnessing mechanisms of post-translational modifications that function in selected recombinant host cells.
USA1 – Modified polynucleotides encoding granulysin – Google Patents
The post transcription control 4000 may be compounds described in or a compound found by methods outlined in International Publication Nos. In one embodiment, the oncology-related primary constructs or oncology-related mmRNA of the present invention may include at least one encoded protein cleavage signal containing at least one protein cleavage site.
Probes may also contain chemically modified bases to increase base-pairing fidelity to the target eitectics and base-pairing strength.
The modified nucleotide is added post-transcriptionally using terminal transferase New England Biolabs, Ipswich, MA according to the manufacturer’s protocol.
Suitable elution solvent composition can be determined ix one skilled in the art. One such example involves the use of lipid encapsulation to enable the effective systemic delivery of polyplex plasmid DNA Heyes et al, Mol Ther.
The present invention provides a method of reducing, eliminating, or preventing tumor growth in a subject in need thereof by increasing the level of an oncology-related polypeptide of interest comprising administering to said subject an isolated polynucleotide encoding said oncology-related polypeptide.
Please refer to the end of the specification for access instructions. In the analysis, the level or concentration of an oncology-related polynucleotide, oncology-related primary construct or oncology-related mmRNA may be an expression level, presence, absence, truncation or alteration of the administered construct.
As a non-limiting example, the core-shell nanoparticle may be used to treat an eye disease or disorder See e.
The NTPs may be selected from, but are not limited to, those described herein including natural and unnatural modified NTPs. In particular embodiments, R 1 is optionally substituted alkyl, and R 2 is hydroxy. Such modifications are within the ordinary skill in the art and are performed without undue experimentation.
Provided are compositions, methods, kits, and reagents for treatment or prevention of disease or conditions in humans and other mammals.
Rthe combination of R and Rthe combination of R and Ror the combination of R eutecitcs and R 3 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl e. In one embodiment, the lipid nanoparticle may be formulated for use in a vaccine such as, but not limited to, against a pathogen.
US20140113960A1 – Modified polynucleotides encoding granulysin – Google Patents
One of ordinary skill in the art will appreciate that the nucleotide analogs or other modification s may be located at any position s of an oncology-related polynucleotide, oncology-related primary ip, or oncology-related mmRNA such that the function of the oncology-related polynucleotide, oncology-related primary construct, or oncology-related mmRNA is not substantially decreased. In certain embodiments, modifications e.
In further embodiments, each of R 1R 1and R 1if present, is, independently, H, halo e. According to the present invention, the first and second flanking regions may range independently fromnucleotides in length e.
USB2 – Modified polynucleotides encoding granulysin – Google Patents
The flanking region may also comprise a 5′ terminal cap The first and second composition may comprise the same or different modified mRNA. It has been discovered that unique poly-A tail lengths provide certain advantages to the oncology-related polynucleotides, oncology-related primary constructs or oncology-related mmRNA of the present ixo. Biodegradable polymers have been previously used to protect nucleic acids other than mmRNA from degradation and been euyectics to result in sustained release of payloads in vivo Rozema et al.
The nanoparticle formulations may be a carbohydrate nanoparticle comprising a carbohydrate carrier and a modified nucleic acid molecule e.
US9216205B2 – Modified polynucleotides encoding granulysin – Google Patents
Tables 2 and 3 provide a listing of exemplary UTRs which may be utilized in the oncology-related primary construct of the present invention as flanking regions. As a non-limiting example, the polymeric material may be gamma irradiated See e. Exemplary modified adenines include compounds of Formula b18 – b Microvasc Res An example method includes fractional recrystallization using a “chiral resolving acid” which is an optically active, salt-forming organic acid.
The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule. The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule.
The surface altering agent may be embedded or enmeshed in the particle’s surface or disposed e. In another embodiment, the length is at least 55 nucleotides.